CA2601129A1 - Crystallisation and purification of glycopyrronium bromide - Google Patents

Crystallisation and purification of glycopyrronium bromide Download PDF

Info

Publication number
CA2601129A1
CA2601129A1 CA002601129A CA2601129A CA2601129A1 CA 2601129 A1 CA2601129 A1 CA 2601129A1 CA 002601129 A CA002601129 A CA 002601129A CA 2601129 A CA2601129 A CA 2601129A CA 2601129 A1 CA2601129 A1 CA 2601129A1
Authority
CA
Canada
Prior art keywords
solvent
product
diastereoisomers
crystallisation
particle size
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002601129A
Other languages
French (fr)
Other versions
CA2601129C (en
Inventor
Andrew Douglas Baxter
Kenneth Walter Sinden
Stefan Kleinebekel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nxera Pharma UK Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2601129A1 publication Critical patent/CA2601129A1/en
Application granted granted Critical
Publication of CA2601129C publication Critical patent/CA2601129C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12Oxygen or sulfur atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/06Anti-spasmodics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Silicates, Zeolites, And Molecular Sieves (AREA)
  • Pyrrole Compounds (AREA)

Abstract

A method for the production of crystalline glycopyrronium bromide, comprises the reaction of glycopyrronium base with methyl bromide in a solvent, in which the solvent is selected such that the diastereoisomeric ratio of the product favours the R,S and S,R diastereoisomers over the R,R, and S,S
diastereoisomers, and separating the desired diastereoisomers by one or more controlled crystallisation steps. This method gives a product having a particle size of narrow distribution.

Description

CRYSTALLISATION AND PURIFICATION OF GLYCOPYRRONIUM BROMIDE
Field of the Invention This invention relates to a method of crystallisation and purification of the anti-muscarinic drug glycopyrronium bromide.
Backaround of the Invention Glycopyrronium bromide (Glycopyrrolate, US Pharmacopeia) is the higher melting (193.2 C-194.5 C) of two possible diastereoisomeric racemates, i.e.
the erythro racemate. Glycopyrronium bromide is manufactured by the method disclosed in US-A-2956062, utilizing N-methylpyrrolidin-3-ol (NMP) and methyl 1o hydroxycyclopentylmandelate (MCPM), as follows:

OH

NMP OH
0%0 N\ ~ O
OMe O N
Na / Heptane \
75-80% GP Base 1) MeBr / Solvent
2) MEK / MeOH Recryst.
15-20%
SOC12 . MeOH STAGE 3 90-95%

%OH OH
OH O
O O N Br CPMA
Glycopyrronium Bromide The initial product from the methylation reaction in methyl ethyl ketone (MEK;
stage 3) is isolated as an approximately 50:50 mixture of the two possible pairs of diastereoisomers. In order to obtain the desired drug, i.e. the racemic mixture of the R,S and S,R pair of diastereoisomers, the R,R / S,S pair is removed by recrystallising the crude product from a mixture of methanol and MEK.
In the established manufacturing process, there is no provision to control the particle size of the drug substance. The large and inconsistent particle size produces a physically unstable drug substance following micronisation. Material is difficult to formulate into a drug product suitable for inhalation.
Further, apart from controlling the melting point, the US Pharmacopeia makes no provision for the determination of the amount of the R,R and S,S
diastereoisomeric pair in the active pharmadeutical ingredient.
Commercially available MCPM may contain high levels of impurities. These impurities react competitively in stage 2, to produce high levels of carried through impurities in glycopyrronium base, and then in the final salt.
Summary of the Invention io This invention relates to the production of glycopyrronium bromide utilising a novel crystallization process (Stage 3 in scheme 1). In addition to high purity, a consistent and fine particle size is controlled by the solvent, e.g. a solvent of the formula R'COR2 or R'COOR2 wherein R' and R2 are each alkyl of 1 to 8 C atoms. In addition, the process preferably comprises also a slow cooling rate in the final crystallization steps. The particle size of glycopyrronium bromide produced by this method ensures a physically stable micronised drug substance that is suitable for formulation into a drug product optimized for inhaled delivery.
In a preferred embodiment of the invention, carrying out the methylation reaction in acetone ensures that the ratio of diastereoisomeric pairs is 60:40 in favour of the 2o desired R,S and S,R pair. This ensures a reduction in the number of recrystallisation steps that are required to remove the R,R/ S,S pair.
Description of the Invention Based on information provided herein, one of ordinary skill in the art can readily determine a solvent that is suitable for use in the invention. While acetone is exemplified, other solvents that may be found suitable include esters, e.g. of acetic acid such as ethyl acetate, and other ketones such as methyl isobutyl ketone (MEK).
In the given formulae, R' and R2 are preferably C1-4alkyl, and R' is preferably methyl. A
higher ketone than acetone is preferred for the recrystallisation.
Impurities are efficiently reduced by carrying out the methylation reaction in 3o acetone compared to MEK. Sequential recrystallisations from MEK / methanol systematically eliminate these impurities alongside the R,R / S,S pair of diastereoisomers.
The overall yield of glycopyrronium bromide as a product of the methylation reaction and subsequent purification steps is typically 20-30%. Additional recrystallisation steps can be added should the material from the any given
3 recrystallisation not meet the preferred specification of not more than 0.2%
R,R/S,S.
The following Example (stage 3 of the 3-stage process shown above) illustrates the invention. "Cold" means a temperature of 0-10 C.
Stage 3: Methylation Reaction in Acetone A solution of crude glycopyrronium base (13.0 kg; 42.8 mol) in acetone (130 L) is treated with methyl bromide gas (4.5 kg; 47.4 mol) over 30 minutes while maintaining a temperature between -5 C and 5 C. The mixture is then warmed to between 15 C
and 25 C and maintained at this temperature for 2 hours to ensure complete crystallisation of the glycopyrronium bromide has taken place. The product is filtered by centrifugation, 1o washed with cold acetone (40-60 L) and collected (15. kg).
Stage 3.1: First Recrvstallisation The material (15 kg) is dissolved at reflux in a mixture of methanol (13.0 L) and MEK (90 L). Additional MEK (135 L) is added and reflux (75-85 C) maintained for 30 minutes. The mixture is then cooled to between -1 0 C and 0 C at a rate of 30 C/hour, allowing controlled crystallisation of a purified product which is filtered by centrifugation, washed with cold MEK (30-50 L) and collected (7 kg). The purity of the product from this first recrystallisation is typically not less than 99% and the diastereoisomeric purity is typically 94-95% (by HPLC).
Stage 3.2: Second Recrystallisation The material (7 kg) is dissolved at reflux in a mixture of methanol (10.2 L) and MEK (45 L). Additional MEK(65 L) is added and reflux (75-85 C) maintained for minutes. The mixture is then cooled to between -10 C and 0 C at a rate of 30 C/hour, allowing controlled crystallisation of a purified product which is filtered by centrifugation, washed with cold MEK (20-30 L) and the product collected (5.3 kg). The purity of the product from this recrystallisation is typically not less than 99.9% and the diastereoisomeric purity is typically not less than 99.5% (by HPLC).
Stage 3.3: Third Recrystallisation The material (5.3 kg) is dissolved at reflux in a mixture of methanol (4.2 L) and MEK (33 L). Additional MEK (47 L) is added and reflux (75-85 C) maintained for minutes. The mixture is then cooled to between -10 C and 0 C at a rate of 30 C
/ hour allowing controlled crystallisation of a purified product that is filtered, washed with cold MEK (20 L) and oven dried. The drug substance is a fine white crystalline solid (4.9 kg).
The purity of the product from this first recrystallisation is typically not less than 99.95%
and the diastereoisomeric purity is typically not less than 99.8% (by HPLC).
4 Analytical Methods This method uses a Waters Alliance 2695 HPLC system with a PDA 996 detector, column oven and Waters Empower data system or equivalent:
Column: Astec Cyclobond 12000; 250 mm x 4.6 mm ID
Temperature: 15 C
Injection Volume: 20 pL
Detection: UV at 230 nM
Run Time: 20 min Mobile Phase: 1.0 M triethyl ammonium acetate buffer solution (5.0 ml) mixed with acetonitrile (750 ml) and HPLC water (245 ml) Flow Rate: 1.0 mi /min Gradient: lsocratic Run times and relative response times for R,S/S,Rglycopyrronium bromide (the drug substance) and the R,R/S,S impurity are as follows:
Approx. Run Time RRT
(mins) R,R/S,S 10.3 0.95 F,q,-s-/ 10.8 1 The method has a limit of detection of 0.03% and a limit of quantification of 0.1 %. The process as described is capable of reproducing a drug substance with not more than 0.2% of the R,R/S,S pair.
A HPLC method has -been developed and validated providing an in-process check and test method to control levels of this impurity to < 0.2% in batches of the drug substance. Due to the efficiency of the crystallization required to meet this specification, all other impurities are eliminated. Impurities carried through from impure MCPM can readily be eliminated in the recrystallisation steps.
Stage 1, Purity of MCPM
Batch GC purity Impurity 1 Impurity 2 MCPM 76.8% 15.9% 3.2%

o 0CO2Me Impurity 1 Impurity 2 Stage 2, Glycopyrronium Base Formation from impure MCPM

Yield HPLC Purity No of Imp >0.1 % Impurity 1.1 8.2 kg (54%) 89.7% 4 8.2%
5.3 kg (36%) 95.2% 7 2.8%

o o O O

Impurity 1.1 Impurity 2.1 Stage 3, Glycopyrronium Bromide Formation and Purification.
Stage Yield HPLC RS,SR RR,SS Imp 1.2 Imp 2.2 3 18 kg 98.0% 61.6 38.4 1.1 0.5 3.1 7 kg 99.5% 94.2 5.8 0.4 ND
3.2 5.3 kg 99.9% 99.6 0.4 0.1 ND
3.3 4.9 kg (29.6%) 99.96% >99.8 <0.2 ND ND
6 o D"'.
\Br N + Br-N

Impurity 1.2 Impurity 2.2 ND = Not Detected This Example validates the purification procedure, demonstrating that even poor quality MCPM can be processed to drug substance of excellent quality. The elimination of these impurities is apparently the consequence of controlled recrystallisation.
Uncontrolled crystallization leads to an impure product with an inconsistent particle size distribution. It was surprising to find the controlled cooling rate employed not only defined a high level of purity but also provided control of particle size distribution and 1o uniform morphological habit, as shown by imaging. Subsequent micronisation of this product has provided a physically stable drug substance that is suitable for formulation into a drug product optimized for inhaled delivery.

Claims (10)

1. A method for the production of crystalline glycopyrronium bromide, which comprises the reaction of glycopyrronium base with methyl bromide in a solvent, in which the solvent is selected such that the diastereoisomeric ratio of the product favours the R,S and S,R diastereoisomers over the R,R, and S,S diastereoisomers, and separating the desired diastereoisomers by one or more controlled crystallisation steps.
2. A method according to claim 1, wherein the reaction solvent and also the solvent in which the crystallization is conducted each comprise the same or different compounds of the formula R1COR2 or R1COOR2 wherein R1 and R2 are independently C1-8 alkyl.
3. A method according to claim 2, wherein the reaction solvent is acetone.
4. A method according to claim 2 or claim 3, wherein the crystallisation solvent comprises methyl ethyl ketone or methyl isobutyl ketone.
5. A method according to claim 4, wherein the crystallisation solvent is a mixture of methyl ethyl ketone and methanol.
6. A method according to any preceding claim, wherein the diastereoisomeric purity of the product is more than 99.8% R,S/S,R.
7. A method according to any preceding claim, wherein the particle size of the product is less than 100 µm.
8. A method according to claim 7, wherein the particle size is less than 50 µm.
9. A method according to any preceding claim, wherein the diastereoisomeric ratio is at least 60:40 in favour of the R,S / S,R- pair.
10. Crystalline glycopyrronium bromide obtainable by a method according to any preceding claim, having a particle size of narrow distribution.
CA2601129A 2005-03-03 2006-03-03 Crystallisation and purification of glycopyrronium bromide Active CA2601129C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0504463.1A GB0504463D0 (en) 2005-03-03 2005-03-03 Method of crystallisation and purification
GB0504463.1 2005-03-03
PCT/GB2006/000770 WO2006092617A1 (en) 2005-03-03 2006-03-03 Crystallisation and purification of glycopyrronium bromide

Publications (2)

Publication Number Publication Date
CA2601129A1 true CA2601129A1 (en) 2006-09-08
CA2601129C CA2601129C (en) 2013-04-30

Family

ID=34451780

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2601129A Active CA2601129C (en) 2005-03-03 2006-03-03 Crystallisation and purification of glycopyrronium bromide

Country Status (21)

Country Link
US (1) US8846954B2 (en)
EP (1) EP1856041B1 (en)
JP (1) JP5319119B2 (en)
KR (1) KR101267108B1 (en)
CN (1) CN101133021B (en)
AT (1) ATE431337T1 (en)
AU (1) AU2006219727B2 (en)
BR (1) BRPI0609057A2 (en)
CA (1) CA2601129C (en)
DE (1) DE602006006808D1 (en)
DK (1) DK1856041T3 (en)
ES (1) ES2326132T3 (en)
GB (1) GB0504463D0 (en)
HK (1) HK1104817A1 (en)
IL (1) IL185576A (en)
MX (1) MX2007010729A (en)
NO (1) NO340220B1 (en)
NZ (1) NZ561293A (en)
PT (1) PT1856041E (en)
WO (1) WO2006092617A1 (en)
ZA (1) ZA200707512B (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090005577A1 (en) * 2007-06-29 2009-01-01 Nikolai Kraiouchkine Method of producing 1-substituted 3-pyrrolates
KR101290893B1 (en) * 2009-04-09 2013-07-29 노파르티스 아게 Process for preparing pyrrolidinium salts
CA2802584C (en) * 2010-06-14 2018-08-21 Chiesi Farmaceutici S.P.A. Crystal form of glycopyrronium chloride
CN103159659A (en) * 2011-12-19 2013-06-19 沈阳药科大学 Preparation method of muscarinic receptor antagonist glycopyrronium bromide
CN102627595A (en) * 2012-03-09 2012-08-08 徐奎 Method for preparation of glycopyrronium bromide
US9006462B2 (en) 2013-02-28 2015-04-14 Dermira, Inc. Glycopyrrolate salts
EP3842419B1 (en) 2013-02-28 2024-04-03 Journey Medical Corporation Method of making threo glycopyrrolate tosylate
US8558008B2 (en) 2013-02-28 2013-10-15 Dermira, Inc. Crystalline glycopyrrolate tosylate
CN103553996B (en) * 2013-11-13 2016-01-20 北京三泉医药技术有限公司 Anticholinergic pharmaceutical composition
US9926270B2 (en) 2014-08-20 2018-03-27 Dermira, Inc. Process for production of glycopyrronium tosylate
CZ2014680A3 (en) 2014-10-06 2016-04-13 Zentiva, K.S. Process for preparing glycopyrronium bromide
US9925168B2 (en) * 2016-01-22 2018-03-27 Chiesi Farmaceutici S.P.A. Preparation of micronized particles of an antimuscarinic compound by hydrodynamic cavitation
CN107345945B (en) * 2016-05-05 2019-12-17 辽宁药联制药有限公司 High performance liquid chromatography method for resolving glycopyrronium bromide enantiomer and checking impurities
PT109445B (en) * 2016-06-08 2018-11-06 Hovione Farm Sa CRYSTALINE PHARMACEUTICAL CO-CRYSTALS OF LACTOSE GLYCOPYRONIUM BROMETTE
CN107915666A (en) * 2016-10-09 2018-04-17 四川海思科制药有限公司 A kind of glycopyrronium bromide compound
WO2022079194A1 (en) 2020-10-14 2022-04-21 Pcas Process for the production of glycopyrronium tosylate
CN113234003B (en) * 2021-04-23 2024-02-02 广东嘉博制药有限公司 Glycopyrronium bromide and preparation method thereof
CN114428131B (en) * 2021-12-27 2023-09-15 山东泰合医药科技有限公司 Detection method for resolving diastereoisomers of glycopyrronium bromide intermediate

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
EP1369414A1 (en) 1996-11-11 2003-12-10 Christian R. Noe Enantiomerically pure Arylcycloalkyl hydroxycarboxylic esters, processes for their preparation and their use as modulators of muscarinic receptors
AT412088B (en) * 2002-12-18 2004-09-27 Pharmacon Forschung & Beratung Gmbh METHOD FOR PRODUCING THE R, R OR S, S CONFIGURED GLYCOPYRRONIUM ISOMERS

Also Published As

Publication number Publication date
JP5319119B2 (en) 2013-10-16
JP2008531674A (en) 2008-08-14
IL185576A0 (en) 2008-01-06
NO20074558L (en) 2007-09-28
ZA200707512B (en) 2008-11-26
MX2007010729A (en) 2007-11-08
AU2006219727A1 (en) 2006-09-08
BRPI0609057A2 (en) 2010-02-17
ATE431337T1 (en) 2009-05-15
CN101133021A (en) 2008-02-27
DK1856041T3 (en) 2009-08-24
IL185576A (en) 2011-11-30
KR20070113263A (en) 2007-11-28
EP1856041A1 (en) 2007-11-21
AU2006219727B2 (en) 2010-03-04
DE602006006808D1 (en) 2009-06-25
CN101133021B (en) 2011-01-19
US8846954B2 (en) 2014-09-30
US20080227988A1 (en) 2008-09-18
NZ561293A (en) 2010-05-28
KR101267108B1 (en) 2013-05-23
WO2006092617A1 (en) 2006-09-08
PT1856041E (en) 2009-07-21
EP1856041B1 (en) 2009-05-13
GB0504463D0 (en) 2005-04-13
CA2601129C (en) 2013-04-30
ES2326132T3 (en) 2009-10-01
NO340220B1 (en) 2017-03-20
HK1104817A1 (en) 2008-01-25

Similar Documents

Publication Publication Date Title
CA2601129C (en) Crystallisation and purification of glycopyrronium bromide
EP1893587B1 (en) Method for producing dihydroquinazolines
EP3174855B1 (en) Coformer salts of (2s,3s)-methyl 7-fluoro-2-(4-fluorophenyl)-3-(1-methyl-1h-1,2,4-triazol-5-yl)-4-oxo-1,2,3,4-tetrahydroquinoline-5-carboxylate and methods of preparing them
JP5277295B2 (en) Method for obtaining pure enantiomers of pyridazinone derivatives
EP2332908A1 (en) Method for purifying aminoacetylpyrrolidinecarbonitrile derivative and salt thereof
JP4500814B2 (en) A novel process for producing imipenem
KR20160008026A (en) Method for the preparation of high purity Rosuvastatin Calcium salt
CN115991673A (en) Purification method of regorafenib

Legal Events

Date Code Title Description
EEER Examination request